199 related articles for article (PubMed ID: 22899868)
21. Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity.
Li X; Zuo Y; Tang G; Wang Y; Zhou Y; Wang X; Guo T; Xia M; Ding N; Pan Z
J Med Chem; 2014 Jun; 57(12):5112-28. PubMed ID: 24915291
[TBL] [Abstract][Full Text] [Related]
22. (S)-armepavine inhibits human peripheral blood mononuclear cell activation by regulating Itk and PLCgamma activation in a PI-3K-dependent manner.
Liu CP; Kuo YC; Shen CC; Wu MH; Liao JF; Lin YL; Chen CF; Tsai WJ
J Leukoc Biol; 2007 May; 81(5):1276-86. PubMed ID: 17284681
[TBL] [Abstract][Full Text] [Related]
23. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
[TBL] [Abstract][Full Text] [Related]
24. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
[TBL] [Abstract][Full Text] [Related]
25. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of Bruton's tyrosine kinase and IL-2 inducible T-cell kinase suppresses both neutrophilic and eosinophilic airway inflammation in a cockroach allergen extract-induced mixed granulocytic mouse model of asthma using preventative and therapeutic strategy.
Nadeem A; Ahmad SF; Al-Harbi NO; Ibrahim KE; Siddiqui N; Al-Harbi MM; Attia SM; Bakheet SA
Pharmacol Res; 2019 Oct; 148():104441. PubMed ID: 31505252
[TBL] [Abstract][Full Text] [Related]
27. itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2.
Siliciano JD; Morrow TA; Desiderio SV
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11194-8. PubMed ID: 1280821
[TBL] [Abstract][Full Text] [Related]
28. Structure-activity relationship investigation for benzonaphthyridinone derivatives as novel potent Bruton's tyrosine kinase (BTK) irreversible inhibitors.
Wang B; Deng Y; Chen Y; Yu K; Wang A; Liang Q; Wang W; Chen C; Wu H; Hu C; Miao W; Hur W; Wang W; Hu Z; Weisberg EL; Wang J; Ren T; Wang Y; Gray NS; Liu Q; Liu J
Eur J Med Chem; 2017 Sep; 137():545-557. PubMed ID: 28628824
[TBL] [Abstract][Full Text] [Related]
29. Rosmarinic acid inhibits Ca2+-dependent pathways of T-cell antigen receptor-mediated signaling by inhibiting the PLC-gamma 1 and Itk activity.
Kang MA; Yun SY; Won J
Blood; 2003 May; 101(9):3534-42. PubMed ID: 12511421
[TBL] [Abstract][Full Text] [Related]
30. Characterization of a novel interaction between transcription factor TFII-I and the inducible tyrosine kinase in T cells.
Sacristán C; Schattgen SA; Berg LJ; Bunnell SC; Roy AL; Rosenstein Y
Eur J Immunol; 2009 Sep; 39(9):2584-95. PubMed ID: 19701889
[TBL] [Abstract][Full Text] [Related]
31. Inhibitors of BTK and ITK: state of the new drugs for cancer, autoimmunity and inflammatory diseases.
Vargas L; Hamasy A; Nore BF; Smith CI
Scand J Immunol; 2013 Aug; 78(2):130-9. PubMed ID: 23672610
[TBL] [Abstract][Full Text] [Related]
32. HIV-1 Nef dimers short-circuit immune receptor signaling by activating Tec-family kinases at the host cell membrane.
Li WF; Aryal M; Shu ST; Smithgall TE
J Biol Chem; 2020 Apr; 295(15):5163-5174. PubMed ID: 32144207
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
Dubovsky JA; Beckwith KA; Natarajan G; Woyach JA; Jaglowski S; Zhong Y; Hessler JD; Liu TM; Chang BY; Larkin KM; Stefanovski MR; Chappell DL; Frissora FW; Smith LL; Smucker KA; Flynn JM; Jones JA; Andritsos LA; Maddocks K; Lehman AM; Furman R; Sharman J; Mishra A; Caligiuri MA; Satoskar AR; Buggy JJ; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2013 Oct; 122(15):2539-49. PubMed ID: 23886836
[TBL] [Abstract][Full Text] [Related]
34. TEC family kinases in health and disease--loss-of-function of BTK and ITK and the gain-of-function fusions ITK-SYK and BTK-SYK.
Hussain A; Yu L; Faryal R; Mohammad DK; Mohamed AJ; Smith CI
FEBS J; 2011 Jun; 278(12):2001-10. PubMed ID: 21518255
[TBL] [Abstract][Full Text] [Related]
35. JAK3, STAT, and MAPK signaling pathways as novel molecular targets for the tyrphostin AG-490 regulation of IL-2-mediated T cell response.
Wang LH; Kirken RA; Erwin RA; Yu CR; Farrar WL
J Immunol; 1999 Apr; 162(7):3897-904. PubMed ID: 10201908
[TBL] [Abstract][Full Text] [Related]
36. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-cell acute lymphoblastic leukemia.
Falà F; Blalock WL; Tazzari PL; Cappellini A; Chiarini F; Martinelli G; Tafuri A; McCubrey JA; Cocco L; Martelli AM
Mol Pharmacol; 2008 Sep; 74(3):884-95. PubMed ID: 18577685
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
38. Discovery of a (1H-benzoimidazol-2-yl)-1H-pyridin-2-one (BMS-536924) inhibitor of insulin-like growth factor I receptor kinase with in vivo antitumor activity.
Wittman M; Carboni J; Attar R; Balasubramanian B; Balimane P; Brassil P; Beaulieu F; Chang C; Clarke W; Dell J; Eummer J; Frennesson D; Gottardis M; Greer A; Hansel S; Hurlburt W; Jacobson B; Krishnananthan S; Lee FY; Li A; Lin TA; Liu P; Ouellet C; Sang X; Saulnier MG; Stoffan K; Sun Y; Velaparthi U; Wong H; Yang Z; Zimmermann K; Zoeckler M; Vyas D
J Med Chem; 2005 Sep; 48(18):5639-43. PubMed ID: 16134929
[TBL] [Abstract][Full Text] [Related]
39. Comparison of interleukin-2-inducible kinase (ITK) inhibitors and potential for combination therapies for T-cell lymphoma.
Mamand S; Allchin RL; Ahearne MJ; Wagner SD
Sci Rep; 2018 Sep; 8(1):14216. PubMed ID: 30242208
[TBL] [Abstract][Full Text] [Related]
40. Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.
Molina-Cerrillo J; Alonso-Gordoa T; Gajate P; Grande E
Cancer Treat Rev; 2017 Jul; 58():41-50. PubMed ID: 28641100
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
